Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

← catalyst calendar

NCT03313778 · readout in 459 d

Sponsored by ModernaTX, Inc. (industry) · MRNA — their whole pipeline →. With Merck Sharp & Dohme LLC.

Phase

Phase 1

Status

Active, not recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

161actual

Sites

Countries

Australia, Japan, United Kingdom +1

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2017-08-14

actual

When the study began enrolling

Primary completion

2027-11-21

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-11-21

estimated

The whole study's end, after follow-up

First posted

2017-10-18

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-03-04

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Solid Tumors

Interventions

Biological: mRNA-4157
Biological: Pembrolizumab
Biological: SoC Treatment — also filed as Standard of care chemotherapy

Primary outcome

what the primary-completion date above is the date OF

Number of Participants with Adverse Events

measured Part A and A2: Baseline through 100 days after last mRNA-4157 dose; Parts B, C, D, E1, E2, and E3: Baseline through 90 days after last pembrolizumab dose

Publications

PMID 39485256 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · MRNA's whole pipeline · Catalyst calendar · Every registered study · What changed